Get started
Work

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

Year: 2016
Type: article
Study design: Case Report
Abstract: RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.
DOI: 10.1159/000444631
Authors: Corey A. Carter, Bryan T. Oronsky, Scott Z. Caroen, Jan J. Scicinski, Aiste Degesys, Michelle M. Kim, Arnold L. Oronsky, Harry Lybeck, Pedro Cabrales, Neil Oronsky, Tony Reid, Joseph Roswarski, Christina Brzezniak
Institutions: Walter Reed National Military Medical Center, EpicentRx, Inc. (United States), University of Michigan, University of Helsinki, University of California San Diego, Moores Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,170
OpenAlex ID: W2307621786
FWCI: 1.621
Cites: 22
Cited by: 11
Related to: 10